These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Noninvasive In Vivo Imaging and Biologic Characterization of Thyroid Tumors by ImmunoPET Targeting of Galectin-3. D'Alessandria C; Braesch-Andersen S; Bejo K; Reder S; Blechert B; Schwaiger M; Bartolazzi A Cancer Res; 2016 Jun; 76(12):3583-92. PubMed ID: 27216181 [TBL] [Abstract][Full Text] [Related]
3. ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. Hernandez R; Sun H; England CG; Valdovinos HF; Barnhart TE; Yang Y; Cai W Mol Pharm; 2016 Jul; 13(7):2563-70. PubMed ID: 27280694 [TBL] [Abstract][Full Text] [Related]
4. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas. de Lucas AG; Schuhmacher AJ; Oteo M; Romero E; Cámara JA; de Martino A; Arroyo AG; Morcillo MÁ; Squatrito M; Martinez-Torrecuadrada JL; Mulero F PLoS One; 2016; 11(7):e0158634. PubMed ID: 27462980 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
6. Expression of galectin-1 and galectin-3 in human fetal thyroid gland. Savin SB; Cvejić DS; Janković MM J Histochem Cytochem; 2003 Apr; 51(4):479-83. PubMed ID: 12642626 [TBL] [Abstract][Full Text] [Related]
7. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Rorive S; Eddafali B; Fernandez S; Decaestecker C; André S; Kaltner H; Kuwabara I; Liu FT; Gabius HJ; Kiss R; Salmon I Mod Pathol; 2002 Dec; 15(12):1294-301. PubMed ID: 12481010 [TBL] [Abstract][Full Text] [Related]
8. Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Bartolazzi A; Bellotti C; Sciacchitano S Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):2-7. PubMed ID: 21691201 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Xu XC; el-Naggar AK; Lotan R Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193 [TBL] [Abstract][Full Text] [Related]
10. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499 [TBL] [Abstract][Full Text] [Related]
12. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Feilchenfeldt J; Tötsch M; Sheu SY; Robert J; Spiliopoulos A; Frilling A; Schmid KW; Meier CA Mod Pathol; 2003 Nov; 16(11):1117-23. PubMed ID: 14614051 [TBL] [Abstract][Full Text] [Related]
13. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102 [TBL] [Abstract][Full Text] [Related]
14. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Aron M; Kapila K; Verma K Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Kawachi K; Matsushita Y; Yonezawa S; Nakano S; Shirao K; Natsugoe S; Sueyoshi K; Aikou T; Sato E Hum Pathol; 2000 Apr; 31(4):428-33. PubMed ID: 10821488 [TBL] [Abstract][Full Text] [Related]
16. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403 [TBL] [Abstract][Full Text] [Related]
17. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560 [TBL] [Abstract][Full Text] [Related]
18. [The expression of galectin-3 in nodular thyroid goitre]. Chen WJ; Yu MH; Xu Y; Shen J Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):452-5. PubMed ID: 16831319 [TBL] [Abstract][Full Text] [Related]
19. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. Saggiorato E; Cappia S; De Giuli P; Mussa A; Pancani G; Caraci P; Angeli A; Orlandi F J Clin Endocrinol Metab; 2001 Nov; 86(11):5152-8. PubMed ID: 11701669 [TBL] [Abstract][Full Text] [Related]
20. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]